PHIBRO ANIMAL HEALTH CORP
Business
Phibro Animal Health Corporation is a global diversified animal health and mineral nutrition company that develops, manufactures and markets approximately 800 product lines in roughly 90 countries. The company offers antibacterials, anticoccidials, nutritional specialty products, vaccines and vaccine adjuvants for livestock including poultry, swine, beef and dairy cattle, aquaculture and dogs, plus mineral nutrition products and specialty industrial chemicals. Products are sold directly to integrated producers or through feed manufacturers, wholesalers, distributors and veterinarians across North America, Latin America, Asia Pacific, Europe, Africa and the Middle East.
Summary from 10-K filed 2025-08-27
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-06-30 | FY 2024 2024-06-30 | FY 2023 2023-06-30 | FY 2022 2022-06-30 | FY 2021 2021-06-30 |
|---|---|---|---|---|---|---|
| Net sales | 1,296 | 1,018 | 978 | 942 | 833 | |
| Cost of goods sold | −896 | −705 | −680 | 657 | 562 | |
| Gross profit | 400 | 313 | 298 | 285 | 271 | |
| Selling, general and administrative expenses | 289 | 260 | 226 | 206 | 197 | |
| Operating income | 110 | 53 | 72 | 79 | 75 | |
| Interest expense, net | 35 | 19 | 15 | 12 | — | |
| Foreign currency losses, net | 8 | 24 | 2 | −5 | −4 | |
| Income before income taxes | 68 | 11 | 54 | 72 | 66 | |
| Provision for income taxes | 20 | 9 | 21 | 23 | 12 | |
| Net income | 48 | 2 | 33 | 49 | 54 | |
| basic (in dollars per share) | 1.19 | 0.06 | 0.81 | 1.21 | 1.34 | |
| diluted (in dollars per share) | 1.19 | 0.06 | 0.81 | 1.21 | 1.34 | |
| basic (in shares) | 41 | 41 | 41 | 41 | 40 | |
| diluted (in shares) | 41 | 41 | 41 | 41 | 41 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-06-30 | FY 2024 2024-06-30 | FY 2023 2023-06-30 | FY 2022 2022-06-30 | FY 2021 2021-06-30 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 68 | 71 | 41 | 74 | 50 | |
| Short-term investments | 9 | 44 | 40 | 17 | 43 | |
| Accounts receivable, net | 228 | 169 | 163 | 167 | 147 | |
| Inventories, net | 444 | 266 | 278 | 259 | 216 | |
| Other current assets | 61 | 51 | 63 | 49 | 43 | |
| Total current assets | 811 | 601 | 586 | 566 | 499 | |
| Property, plant and equipment, net | 355 | 203 | 196 | 165 | 155 | |
| Intangibles, net | 36 | 45 | 55 | 64 | 62 | |
| Goodwill | 60 | 55 | 53 | 53 | 53 | |
| Other assets | 99 | 78 | 82 | 83 | 73 | |
| Total assets | 1,361 | 982 | 971 | 932 | 841 | |
| Current portion of long-term debt | 16 | 30 | 22 | 15 | 9 | |
| Accounts payable | 138 | 86 | 74 | 96 | 68 | |
| Accrued expenses and other current liabilities | 139 | 89 | 80 | 80 | 86 | |
| Total current liabilities | 293 | 204 | 176 | 191 | 164 | |
| Revolving credit facility | 87 | 176 | 141 | 145 | 95 | |
| Long-term debt | 615 | 282 | 312 | 273 | 288 | |
| Other liabilities | 79 | 63 | 60 | 61 | 56 | |
| Total liabilities | 1,075 | 726 | 689 | 669 | 603 | |
| Commitments and contingencies (Note 13) | — | — | — | — | — | |
| Common stock, par value $0.0001 per share; 300,000,000 Class A shares authorized, 20,367,574 shares issued and outstanding at June 30, 2025, and 20,337,574 shares issued and outstanding at June 30, 2024; 30,000,000 Class B shares authorized, 20,166,034 shares issued and outstanding at June 30, 2025, and June 30, 2024 | 4,000 | 4,000 | 4,000 | 4,000 | 4,000 | |
| Paid-in capital | 137 | 136 | 136 | 136 | 136 | |
| Retained earnings | 273 | 244 | 261 | 248 | 218 | |
| Accumulated other comprehensive loss | −124 | −124 | −114 | −121 | −115 | |
| Total stockholders' equity | 286 | 257 | 283 | 262 | 239 | |
| Total liabilities and stockholders' equity | 1,361 | 982 | 971 | 932 | 841 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-06-30 | FY 2024 2024-06-30 | FY 2023 2023-06-30 | FY 2022 2022-06-30 | FY 2021 2021-06-30 |
|---|---|---|---|---|---|---|
| Net income | 48 | 2 | 33 | 49 | 54 | |
| Depreciation and amortization | 46 | 36 | 34 | 33 | 32 | |
| Amortization of debt issuance costs | 2 | 1 | 727,000 | 590,000 | 833,000 | |
| Deferred income taxes | −5 | −12 | −3 | −806,000 | −2 | |
| Foreign currency losses (gains), net | 600,000 | 13 | −10 | −5 | −10 | |
| Acquisition-related items | 6 | 521,000 | — | 316,000 | — | |
| Non-cash impairment charges | 5 | — | — | — | — | |
| Pension settlement cost | — | 11 | — | — | — | |
| Brazil employment taxes | — | 4 | — | — | — | |
| Stock-based compensation expense | 717,000 | 475,000 | — | — | 1 | |
| Other | −2 | −2 | 334,000 | 319,000 | 2 | |
| Accounts receivable, net | −55 | −9 | 5 | −24 | −18 | |
| Inventories, net | −44 | 3 | −11 | −47 | −12 | |
| Other current assets | −16 | 11 | −7 | −2 | −2 | |
| Other assets | 2 | 4 | 750,000 | −2 | −2 | |
| Accounts payable | 46 | 12 | −23 | 26 | 3 | |
| Accrued expenses and other liabilities | 47 | 12 | −6 | 3 | 1 | |
| Net cash provided by operating activities | 80 | 88 | 13 | 32 | 48 | |
| Purchases of short-term investments | −14 | −66 | −40 | −64 | −74 | |
| Maturities of short-term investments | 49 | 62 | 17 | 90 | 86 | |
| Capital expenditures | −38 | −41 | −52 | −37 | −29 | |
| Business acquisition, net of cash acquired | −287 | −3 | — | −14 | — | |
| Other, net | 1 | 326,000 | 776,000 | 620,000 | −1 | |
| Net cash used by investing activities | −289 | −48 | −74 | −23 | −19 | |
| Revolving credit facility borrowings | 532 | 276 | 264 | 297 | 318 | |
| Revolving credit facility repayments | −621 | −241 | −268 | −247 | −392 | |
| Proceeds from long-term debt | 650 | — | 62 | — | 300 | |
| Payments of long-term debt | −325 | −22 | −15 | −9 | −221 | |
| Debt issuance costs | −10 | — | −1 | — | −3 | |
| Proceeds from insurance premium financing and other short-term debt | 8 | 9 | 6 | — | — | |
| Payments of insurance premium financing and other short-term debt | −7 | −9 | −1 | — | — | |
| Dividends paid | −19 | −19 | −19 | −19 | −19 | |
| Net cash provided (used) by financing activities | 207 | −7 | 27 | 16 | −17 | |
| Effect of exchange rate changes on cash | −1 | −3 | 754,000 | −1 | 1 | |
| Net (decrease) increase in cash and cash equivalents | −3 | 29 | −33 | 24 | 14 | |
| Interest paid, net | 32 | 17 | 15 | 11 | 11 | |
| Income taxes paid, net | 13 | 15 | 20 | 18 | 19 | |
| Property, plant and equipment | 7 | 2 | 3 | 3 | 3 |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is PHIBRO ANIMAL HEALTH CORP's CIK number?
PHIBRO ANIMAL HEALTH CORP's SEC CIK number is 0001069899 (1069899). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find PHIBRO ANIMAL HEALTH CORP's SEC filings?
All of PHIBRO ANIMAL HEALTH CORP's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did PHIBRO ANIMAL HEALTH CORP last report earnings?
PHIBRO ANIMAL HEALTH CORP (PAHC) most recently filed an earnings 8-K with the SEC on May 6, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001104659-26-056316). This is PHIBRO ANIMAL HEALTH CORP's most recent earnings filing of record — not a forecast of its next earnings date.
What is PHIBRO ANIMAL HEALTH CORP's most recent earnings 8-K?
PHIBRO ANIMAL HEALTH CORP's latest earnings 8-K (Item 2.02) was filed May 6, 2026 under accession 0001104659-26-056316. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View PHIBRO ANIMAL HEALTH CORP's latest earnings 8-K →
Look up any company's CIK number →